Me, the popular at-home genetic testing company, has helped millions of people uncover their family roots and health risks through DNA analysis. Experts fear as the company faces financial issues they ...

The future of 23andMe, a genetic testing company, is uncertain due to financial challenges and recent workforce reductions.

In the year since its hack, 23andMe has lost all of its value and most of its governing board — and somehow, things just keep ...

Me announces 40% workforce reduction and cancellation of therapeutic programs following year of security breaches and ...

Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

Me just dropped some major news in a tough year for the genetic testing company. After months of financial challenges, data ...

CEO Anne Wojcicki has said she intends to take the company private and is not considering third-party takeover proposals.

The genetic testing company 23andMe hasn't been doing so hot lately, watching its share price plummet more than 70% this year ...

The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile ...

The genetic testing firm will also close its drug development arm. CEO Anne Wojcicki said the cuts are necessary to “focus on ...

CEO Anne Wojcicki, who holds roughly half of the voting power, is attempting to take the company private. In September, seven ...